Skip to main content

Table 3 Number and proportion of patients with at least one adverse event

From: Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania

Adverse events

Kibaha (n = 80)

Ujiji (n = 88)

Mkuzi (n = 88)

Mlimba (n = 88)

Total (n = 344)

Cough

0 (0%)

12 (13.6%)

31 (35.2%)

1 (1.1%)

44 (12.8%)

Abdominal pain

2 (2.5%)

1 (1.1%)

12 (13.6%)

0 (0%)

15 (4.4%)

Vomiting

3 (3.8%)

0 (0%)

9 (10.2%)

1 (1.1%)

13 (3.8%)

Diarrhoea

0 (0%)

0 (0%)

3 (3.4%)

1 (1.1%)

4 (1.2%)

Headache

1 (1.3%)

0 (0%)

1 (1.1%)

0 (0%)

2 (0.6%)

Others

0 (0%)

10 (11.4%)

5 (3.4%)

3 (3.4%)

18 (5.2%)

Total

6 (7.5%)

23 (26.1%)

61 (69.3%)

6 (6.8%)

96 (27.9%)